We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Portable Sensor Rapidly Determines Extent of Eye Injury

By LabMedica International staff writers
Posted on 14 Dec 2015
Print article
Image: The new OcuCheck Biosensor can detect differences in vitamin C concentration in fluids that leak from the eye, where higher concentrations indicate a more severe injury, researchers report (Photo courtesy of L. Brian Stauffer and University of Illinois).
Image: The new OcuCheck Biosensor can detect differences in vitamin C concentration in fluids that leak from the eye, where higher concentrations indicate a more severe injury, researchers report (Photo courtesy of L. Brian Stauffer and University of Illinois).
Researchers have demonstrated a proof-of-concept for a novel point-of-care (POC) device that can quickly and inexpensively determine whether an eye injury is mild or severe. The sensor could speed efforts to determine extent of eye injury at locations such as accident sites, rural areas lacking ophthalmology specialists, and battlefields.

The new “OcuCheck Biosensor” works by measuring vitamin C levels in the fluids that coat or leak from the eye, and was developed by a team led by Prof. Dipanjan Pan, Bioengineering, University of Illinois (Champaign, IL, USA) in collaboration with Dr. Leanne Labriola, ophthalmologist at Carle (Urbana, IL, USA). “The sensor takes advantage of the fact that the ocular tear film—the viscous fluid that coats the eyeball—contains low levels of ascorbic acid, which is just vitamin C, while the interior of the eye contains much higher levels,” said Prof. Pan, “So the concept is, if there is severe damage to the eye that penetrates deeply, the ascorbic acid will leak out in high concentration.”

Currently, patients must reach a hospital to have eye injuries assessed for degree of severity. The process is often complicated, time-consuming, and imprecise. No current techniques for assessing eye injuries involve measurements of ascorbic acid (AA) “so this is a one-of-a-kind approach,” said Prof. Pan. “The new device will change the standard of care for evaluating eye traumas,” said Dr. Labriola.

OcuCheck uses graphene platelets layered 1 nm thick on filter paper. Upper layers include a unique polymer that interacts with the graphene, gold electrodes, and ascorbate oxidase, which binds to AA. “The idea is that the moment that the AA comes in and binds to the ascorbate oxidase, it will pull the polymer out of its interaction with the graphene,” changing the sensor’s electrical properties, said Prof. Pan.

Proof-of-concept was demonstrated by testing clinical samples from 16 patients undergoing eye surgery. OcuCheck coul—with high sensitivity, accuracy, and specificity—detect a range of AA concentrations. OcuCheck has not yet been tested on samples from trauma patients “but we have mixed the samples with blood, and the sensor’s sensitivity to AA is retained even in the presence of blood. The filter paper will filter out the blood,” said Prof. Pan.

The team is working with an industrial design professor to build a housing unit for the sensor. Prof. Pan and Dr. Labriola have founded a startup company, InnSight Technology, to help bring the device to market. “This is a perfect example of physicians and engineers working together to find solutions to current problems in health care,” said Prof. Pan, also referring to the Carle Illinois College of Medicine Carle Illinois College of Medicine (Urbana, IL, USA), a new engineering-based medical college soon to be established.

The paper, by Gartia MR, Misra SK et al., was published online in November 2015, in the journal Scientific Reports.

Related Links:

University of Illinois 
Carle
Carle Illinois College of Medicine


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.